Аннотация:
The article deals with the modern tactics of pulmonary hypertension therapy, used in case of unsatisfactory clinical response to previous therapy. All classes of pathogenetic therapy of pulmonary hypertension are presented, as well as modern views on the risk stratification of annual mortality of patients. Switching to a more effective drug both within one group of pathogenetic PAHtherapy, and to drugs of other classes is discussed. The latest classification of pulmonary hypertension (Nice, 2018) is presented. © 2018 Limited Liability Company KlinMed Consulting. All Rights Reserved.
Ключевые слова:
Bosentan; Combination therapy; Idiopathic pulmonary arterial hypertension; Intravenous epoprostenol; Macitentan; Riociguat; Sildenafil; Tadalafil; Treprostinil
human; pulmonary hypertension; Humans; Hypertension, Pulmonary
Царева Н. А. Наталья Анатольевна 1972-
Авдеев С. Н. Сергей Николаевич 1968-
Tsareva N. A. Natal`ya Anatolyevna 1972-
Avdeev S. N. Sergej Nikolaevich 1968-
New tactics for the treatment of pulmonary hypertension: Switching to a more effective therapy [Новая тактика лечения легочной гипертензии: переключение на более эффективную терапию]
New tactics for the treatment of pulmonary hypertension: Switching to a more effective therapy [Новая тактика лечения легочной гипертензии:...
Текст визуальный непосредственный
Кардиология
Общество специалистов по сердечной недостаточности
Т. 58, Вып. 12 С. 93-100
2018
Статья
Bosentan Combination therapy Idiopathic pulmonary arterial hypertension Intravenous epoprostenol Macitentan Riociguat Sildenafil Tadalafil Treprostinil
human pulmonary hypertension Humans Hypertension, Pulmonary
The article deals with the modern tactics of pulmonary hypertension therapy, used in case of unsatisfactory clinical response to previous therapy. All classes of pathogenetic therapy of pulmonary hypertension are presented, as well as modern views on the risk stratification of annual mortality of patients. Switching to a more effective drug both within one group of pathogenetic PAHtherapy, and to drugs of other classes is discussed. The latest classification of pulmonary hypertension (Nice, 2018) is presented. © 2018 Limited Liability Company KlinMed Consulting. All Rights Reserved.